Detalhe da pesquisa
1.
Adjuvant therapy in renal cell carcinoma.
Cancer
; 125(17): 2935-2944, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31225907
2.
Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.
Invest New Drugs
; 37(3): 559-566, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31037562
3.
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
J Clin Oncol
; 38(27): 3088-3094, 2020 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32491962
4.
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.
Cancer Manag Res
; 11: 7253-7262, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31534371
5.
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Am J Cancer Res
; 8(12): 2359-2376, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30662797
6.
A Case of Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Metaplastic Breast Cancer.
JCO Precis Oncol
; 7: e2200506, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37196220